Duration of Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation in Diabetic and Non-Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

[1]  C. Lavie,et al.  Duration of Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation: A Systematic Review and Meta-analysis of Randomized Controlled Trials. , 2017, Current problems in cardiology.

[2]  Jason E. Moore,et al.  Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus. , 2017, Journal of the American College of Cardiology.

[3]  Antonio Colombo,et al.  Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials , 2016, British Medical Journal.

[4]  Samin K. Sharma,et al.  Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients With and Without Acute Coronary Syndrome: A Systematic Review of Randomized Controlled Trials. , 2016, Mayo Clinic proceedings.

[5]  Samin K. Sharma,et al.  Duration of dual antiplatelet therapy after various drug-eluting stent implantation. , 2016, International journal of cardiology.

[6]  J. Spertus,et al.  Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. , 2016, JAMA.

[7]  Y. Hayashi,et al.  Antiplatelet therapy discontinuation and stent thrombosis after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher Registry. , 2015, International journal of cardiology.

[8]  E. Vicaut,et al.  Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial. , 2015, European heart journal.

[9]  Seung‐Jung Park,et al.  Duration of Dual Antiplatelet Therapy After Coronary Stenting: A Review of the Evidence. , 2015, Journal of the American College of Cardiology.

[10]  G. Stone,et al.  Long-Term Safety of Drug-Eluting and Bare-Metal Stents: Evidence From a Comprehensive Network Meta-Analysis. , 2015, Journal of the American College of Cardiology.

[11]  Giuseppe Biondi-Zoccai,et al.  Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials , 2015, The Lancet.

[12]  Walter Desmet,et al.  ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. , 2015, European heart journal.

[13]  G. Lip,et al.  Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials , 2015, BMJ : British Medical Journal.

[14]  Samin K. Sharma,et al.  Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. , 2015, Journal of the American College of Cardiology.

[15]  L. Mauri,et al.  Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis , 2015, The Lancet.

[16]  A. Jaffe,et al.  2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[17]  Braunwald,et al.  Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. , 2014, The New England journal of medicine.

[18]  E. Vicaut,et al.  Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial , 2014, The Lancet.

[19]  G. Grunwald,et al.  Mortality after presentation with stent thrombosis is associated with time from index percutaneous coronary intervention: a report from the VA CART program. , 2014, American heart journal.

[20]  E. Grove,et al.  The influence of type 2 diabetes on fibrin clot properties in patients with coronary artery disease , 2014, Thrombosis and Haemostasis.

[21]  E. Herzog,et al.  Meta-analysis of randomized clinical trials comparing short-term versus long-term dual antiplatelet therapy following drug-eluting stents. , 2014, The American journal of cardiology.

[22]  M. Jeong,et al.  Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: A Randomized, Controlled Trial , 2014, Circulation.

[23]  Deepak L. Bhatt,et al.  Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. , 2013, JAMA.

[24]  P. Serruys,et al.  Long-term outcome of the unrestricted use of everolimus-eluting stents compared to sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients: the Bern-Rotterdam diabetes cohort study. , 2013, International journal of cardiology.

[25]  M. Joner,et al.  Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography , 2013, Heart.

[26]  Y. Jang,et al.  A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). , 2012, Journal of the American College of Cardiology.

[27]  Deepak L. Bhatt,et al.  Short- and Long-Term Outcomes With Drug-Eluting and Bare-Metal Coronary Stents: A Mixed-Treatment Comparison Analysis of 117 762 Patient-Years of Follow-Up From Randomized Trials , 2012, Circulation.

[28]  O. Boutaud,et al.  Suboptimal Inhibition of Platelet Cyclooxygenase-1 by Aspirin in Metabolic Syndrome , 2012, Hypertension.

[29]  Marc P. Bonaca,et al.  American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therape , 2012, Circulation.

[30]  M. Jeong,et al.  Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) Randomized, Multicenter Study , 2012, Circulation.

[31]  Jeroen J. Bax,et al.  2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). , 2011, European heart journal.

[32]  D. Angiolillo,et al.  Diabetes and Antiplatelet Therapy in Acute Coronary Syndrome , 2011, Circulation.

[33]  O. Deveci,et al.  Aspirin resistance is associated with glycemic control, the dose of aspirin, and obesity in type 2 diabetes mellitus. , 2010, The Journal of clinical endocrinology and metabolism.

[34]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.

[35]  I. Liu,et al.  Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions. , 2008, Journal of the American College of Cardiology.

[36]  J. Badimón,et al.  Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease , 2008, Thrombosis and Haemostasis.

[37]  P. Gurbel,et al.  The Effect of Aspirin Dosing on Platelet Function in Diabetic and Nondiabetic Patients , 2007, Diabetes.

[38]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[39]  I. Iakovou,et al.  Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. , 2005, JAMA.

[40]  C. Davidson,et al.  Diabetes and coronary revascularization. , 2005, JAMA.

[41]  W. O’Neill,et al.  Impact of Sirolimus-Eluting Stents on Outcome in Diabetic Patients: A SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) Substudy , 2004, Circulation.

[42]  J. Beckman,et al.  Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I , 2013, European heart journal.

[43]  V. Fuster,et al.  Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control. , 2001, Journal of the American College of Cardiology.

[44]  M. Bourassa,et al.  Management of coronary artery disease: therapeutic options in patients with diabetes. , 2000, Journal of the American College of Cardiology.

[45]  T. B. Investigators,et al.  Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI) , 1997, Circulation.

[46]  Deepak L. Bhatt,et al.  Short- versus long-term dual antiplatelet therapy after drug-eluting stent implantation: an individual patient data pairwise and network meta-analysis. , 2015, Journal of the American College of Cardiology.